Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science.
At his previous firm, Dutch firm HAL Allergy, de Kam was in charge of clinical development for pollen and dust mites, two key product development areas for Allergy.
Piggot, meanwhile, has significant experience of taking respiratory development programs through Phase I to IV trials and will be responsible for the delivery of Allergy's clinical strategy and products pipeline.
In addition, Tim Higenbottam has been appointed to the position of senior pharmaceutical physician and will focus on the US regulatory process.
Murray Skinner, Allergy’s chief scientific officer of Allergy Therapeutics, said the trio’s vast experience and expert knowledge was ideal to help bring new and convenient into the allergy immunotherapy market."